Theravance Biopharma (NASDAQ:TBPH) Stock Crosses Below Fifty Day Moving Average of $8.90

Theravance Biopharma, Inc. (NASDAQ:TBPH)’s stock price passed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $8.90 and traded as low as $8.05. Theravance Biopharma shares last traded at $8.14, with a volume of 157,062 shares traded.

Analyst Upgrades and Downgrades

TBPH has been the subject of a number of research reports. HC Wainwright reduced their price objective on Theravance Biopharma from $20.00 to $15.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Leerink Partners cut shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $15.00 to $10.00 in a research note on Tuesday, August 6th. StockNews.com lowered Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, August 10th. TD Cowen cut their price target on Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating for the company in a research note on Tuesday, August 6th. Finally, Leerink Partnrs downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 6th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, Theravance Biopharma has a consensus rating of “Hold” and an average price target of $13.75.

Theravance Biopharma Stock Up 0.6 %

The business’s fifty day moving average price is $8.90 and its 200 day moving average price is $8.96. The firm has a market capitalization of $398.21 million, a PE ratio of -9.47 and a beta of 0.24.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.25). The business had revenue of $14.26 million during the quarter, compared to analyst estimates of $15.81 million. Theravance Biopharma had a negative net margin of 73.61% and a negative return on equity of 21.29%. During the same quarter last year, the firm posted ($0.28) earnings per share. As a group, sell-side analysts forecast that Theravance Biopharma, Inc. will post -0.97 earnings per share for the current fiscal year.

Insider Transactions at Theravance Biopharma

In other news, major shareholder Eli Samaha acquired 999,800 shares of the company’s stock in a transaction dated Wednesday, August 7th. The stock was acquired at an average cost of $7.80 per share, for a total transaction of $7,798,440.00. Following the acquisition, the insider now directly owns 9,511,150 shares in the company, valued at approximately $74,186,970. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the sale, the senior vice president now directly owns 335,965 shares in the company, valued at $3,023,685. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Eli Samaha acquired 999,800 shares of the company’s stock in a transaction dated Wednesday, August 7th. The stock was acquired at an average cost of $7.80 per share, with a total value of $7,798,440.00. Following the transaction, the insider now directly owns 9,511,150 shares of the company’s stock, valued at $74,186,970. The disclosure for this purchase can be found here. Insiders own 6.90% of the company’s stock.

Institutional Trading of Theravance Biopharma

Large investors have recently added to or reduced their stakes in the stock. Jacobs Levy Equity Management Inc. boosted its position in shares of Theravance Biopharma by 41.6% in the first quarter. Jacobs Levy Equity Management Inc. now owns 557,971 shares of the biopharmaceutical company’s stock worth $5,005,000 after buying an additional 163,951 shares during the period. Marshall Wace LLP boosted its holdings in Theravance Biopharma by 83.6% in the 2nd quarter. Marshall Wace LLP now owns 297,499 shares of the biopharmaceutical company’s stock worth $2,523,000 after acquiring an additional 135,426 shares during the period. Squarepoint Ops LLC acquired a new stake in Theravance Biopharma in the second quarter valued at approximately $986,000. Wellington Management Group LLP raised its stake in shares of Theravance Biopharma by 68.0% during the fourth quarter. Wellington Management Group LLP now owns 287,102 shares of the biopharmaceutical company’s stock valued at $3,227,000 after purchasing an additional 116,164 shares during the period. Finally, Bank of Montreal Can lifted its position in shares of Theravance Biopharma by 141.0% during the second quarter. Bank of Montreal Can now owns 160,138 shares of the biopharmaceutical company’s stock worth $1,414,000 after purchasing an additional 93,702 shares in the last quarter. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.